|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Steven A. Nichtberger||Co-Founder, Chairman, CEO & Pres||782,16k||N/D||1961|
|Mr. Anup Marda M.B.A.||Chief Financial Officer||548,2k||N/D||1977|
|Dr. Gwendolyn K. Binder||Exec. VP of Science & Technology||582,89k||N/D||1975|
|Dr. Michael C. Milone M.D., Ph.D.||Co-Founder & Co-Chair of Scientific Advisory Board||N/D||N/D||N/D|
|Dr. Aimee Payne M.D., Ph.D.||Co-Founder & Co-Chair of Scientific Advisory Board||N/D||N/D||N/D|
|Mr. J. Brian Stalter J.D.||Gen. Counsel||N/D||N/D||1972|
|Ms. Martha O'Connor||Chief HR Officer||N/D||N/D||N/D|
|Dr. David J. Chang M.D., M.P.H.||Chief Medical Officer||N/D||N/D||1963|
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.
L'ISS Governance QualityScore di Cabaletta Bio, Inc. al 22 gennaio 2021 è 10. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 9; diritti degli azionisti: 10; retribuzione: 9.